Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temferon in previously treated metastatic renal cell carcinoma
2024-512898-27-00Phase 2Completed
- Sponsor
- Genenta Science
- Start
- Sep 2024
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Temferon in renal cell carcinoma (RCC), sponsored by Genenta Science. Primary endpoints: Tolerability and safety of conditioning and Temferon and Biological activity of Temferon in tumor tissue. Started Sep 2024; status: completed.
02
Drugs
Temferon
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-512898-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512898-27-00.